Navigation Links
Nephros Reports 2008 First Quarter Financial Results
Date:5/15/2008

et and the availability of funding sources for continued development of such products and other statements that are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. For such statements, the Company claims the protection of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) Nephros may not be able to obtain funding if and when needed or on terms favorable to it in order to continue operations or fund its clinical trials; (ii) Nephros may not be able to continue as a going concern; (iii) Nephros may not be able to liquidate its short-term investments when needed to fund its operations; (iv) Nephros may be unable to maintain compliance with the American Stock Exchange's continued listing standards; (v) products that appeared promising to Nephros in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials; (vi) Nephros may not obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (vii) Nephros may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures; (viii) HDF therapy may not be accepted in the United States and/or Nephros' technology and products may not be accepted in current or future target markets, which could lead to failure to achieve market penetration of Nephros' products; (
'/>"/>

SOURCE Nephros, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
2. Nephros Strengthens Commercialization Team with Addition of Marketing Executive
3. PreMD Reports First Quarter Results
4. Lifeway Foods Reports Record 1st Quarter 2008 Results
5. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
6. Tiens Biotech Group (USA) Reports First Quarter Results
7. Cardiogenesis Reports First Quarter 2008 Results
8. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
9. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
10. The Female Health Company Reports 267% Increase in Second Quarter Earnings
11. NicOx Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/24/2015)... Rosa, CA (PRWEB) May 24, 2015 ... a clear indicator that the single best option for ... study reveals that fitness level was the single most ... accounted for variables such as diabetes and family history ... significance of maintaining lifelong heart and lung fitness. , ...
(Date:5/23/2015)... May 23, 2015 On May 13, ... of a youngster's yogic power learned through meditation and ... Swami in Bangalore, India. , Yogamaatha, a nine-year-old girl ... 50 high profile professionals attending the 2015 Business Advocacy ... fluently -- blindfolded. , In a demonstration that ...
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... CO (PRWEB) May 23, 2015 On May ... in MuckFest. The event was a 5k mud obstacle run ... more than 2 million people worldwide, and the reason we ... community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred ... Multiple Sclerosis Society.” , The event was not only attended ...
Breaking Medicine News(10 mins):Health News:Medicx Media Solutions Expands Executive Team 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... DUCTZ offers advice in recognition of National Headache ... According to the National,Headache Foundation (NHF), the ... DUCTZ Indoor Air Professionals, the nation,s leading air ... between poor,indoor air quality and headache triggers. According ...
... of Non-invasive Diabetes Screening Device By Year End, ... a privately,held medical device company, announced the completion ... to $20 million to complete the company,s,pivotal clinical ... VeraLight SCOUT DS(TM) non-invasive diabetes screening system. The,current ...
... taken a major step in making the use of artificial ... a study published in the June 2008 print issue of ... developed this artificial graft tissue by combining man-made materials with ... it can attach to host tissue. , "Obviously this advance ...
... Va. and BOSTON, June 3 Most U.S.,medical ... caused by,pharmaceutical industry marketing. Only 21 of 150 ... (AMSA) have strong policies,(those graded A or B), ... AMSA collaborated with The Prescription Project, an industry ...
... joimax(R) company in,Karlsruhe, Germany, is the first company ... for the treatment of spinal canal,stenosis. Having this ... narrow the spinal canal and drastically limit,the motoric ... so called 360,degree TESSYS(TM) Spinal Stenosis System, which ...
... childhood pneumococcal conjugate vaccine has been a boon in ... and the medical community must not get complacent, as ... rise, say scientists at a meeting today in Boston. ... the total burden of pneumococcal disease. It targets ...
Cached Medicine News:Health News:Poor Indoor Air Quality Can Be Excellent Headache Trigger 2Health News:VeraLight Secures $20 Million Series C Financing 2Health News:VeraLight Secures $20 Million Series C Financing 3Health News:Scientists develop 'cyborg engineering' for coronary bypass grafting 2Health News:AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an 'A' 2Health News:AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an 'A' 3Health News:AMSA PharmFree Scorecard Grades U.S. Medical Schools on Conflict-of-Interest Policies; Only 7 Receive an 'A' 4Health News:joimax(R) Revolutionizes Spine Surgery With the Launch of Newest and Fully-Endoscopic Product Innovations to Treat Spinal Canal Stenosis 2Health News:joimax(R) Revolutionizes Spine Surgery With the Launch of Newest and Fully-Endoscopic Product Innovations to Treat Spinal Canal Stenosis 3Health News:Despite vaccine, public should not get complacent about pneumococcal disease 2
(Date:5/22/2015)... 22, 2015  The Mesothelioma Victims Center is ... mesothelioma get the best possible compensation, and they are ... this rare cancer caused by exposure to asbestos ... related to treatment options such as a recent ... Mesothelioma Victims Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)... 22, 2015  In a sweeping analysis assessing the ... T1D Exchange researchers conclude that there remains considerable ... across all age groups, but especially for adolescents and ... of diabetes treatment, underscoring the need to address barriers ... can help type 1 patients achieve optimal metabolic control. ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... The American Association for Homecare urges the Joint Select ... budgetary spending cuts that will restrict access to ... to Congress. Over the years, homecare has broadened health ... cost-savings in the health care system by keeping seniors ...
... LAKES, N.J. and MONTREAL, Oct. 13, 2011 The ... Solutions, Inc. (NYSE: MHS ), and Quest ... showed a statistically significant increase in adherence to statin ... 6 (KIF6) gene testing, compared with those who did ...
Cached Medicine Technology:American Association for Homecare Calls on Joint Deficit Committee in Congress to Preserve Homecare Access for Millions of Americans 2Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement 2Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement 3Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement 4
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma....
The ProteomeLab PA 800 resolves and quantifies proteins by their isoelectric point and molecular weight, generates high-resolution peptide maps and carbohydrate profiles and provides front-end separa...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
For the quantitative determination of alkaline phosphatase in human serum....
Medicine Products: